1. Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
   Kenji Omae et al, 2017, Urologic Oncology: Seminars and Original Investigations CrossRef
2. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis
   Zhun Wang et al, 2017, Clinica Chimica Acta CrossRef
3. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein as new and simple prognostic factors in metastatic renal cell cancer patients treated with tyrosine kinase inhibitors: a systemic review and meta-analysis
   Semeniuk-Wojtaś Aleksandra et al, 2018, Clinical Genitourinary Cancer CrossRef
4. Clinical Decision Analysis of First-line Regimens for Advanced Recurrent Renal Cell Carcinoma
   Toshihiro Shida et al, 2017, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) CrossRef
5. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan
   Kenichi Harada et al, 2018, Int. J. Urol. CrossRef
6. Cost-effectiveness Analysis of Sunitinib and Sorafenib Sequential Treatment of Metastatic Renal Cell Carcinoma
   Toshihiro Shida et al, 2017, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) CrossRef
7. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
   Mototsugu Oya et al, 2017, Cancer Sci CrossRef
8. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan
   Hideaki Miyake et al, 2016, Targ Oncol CrossRef
9. Pharmacotherapies for renal cell carcinoma in Japan
   Kazuhiro Yoshimura et al, 2016, Int. J. Urol. CrossRef
10. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus
    S. Vázquez Estévez et al, 2020, Clin Transl Oncol CrossRef
11. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
    Ondrej Fiala et al, 2020, Cancers CrossRef
12. Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study
    Kojiro Ohba et al, 2023, Int J of Urology CrossRef
13. Association between a novel nutrition‐inflammation prognostic grading system and overall survival in hospitalized adults with cancer: A retrospective cohort study
    Jia‐Xin Huang et al, 2024, J Parenter Enteral Nutr CrossRef